Fidelity Investments, Inc.

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of life science executive, Linda C. Bain, to its Board of Directors. Ms. Bain is a Venture Partner at Atlas Venture and currently serves as a Board Advisor to Remix Therapeutics. “Linda brings more than 20 years of financial, operational and executive leadership success at innovative life science companies,” said Matt Patterson, Chairman of Remix Therapeutics Board of Directors. “Her substantial knowledge and experience successfully managing organizations through significant periods of growth will be invaluable to support Remix as it advances its innovative clinical-stage and discovery programs.” “Having partnered with Linda in her role as Board Advisor to Remix, we are excited to have her join our Board of Directors,” said Pete Smith, PhD, Co-Founder and Chief Executive Officer of Remix Therapeutics. “Linda’s impressive track record of leading financial and operational strategy for both private and publicly held biopharmaceutical companies will be beneficial to Remix’s evolution and achieving our goals.” Prior to Atlas Venture, Ms. Bain served as Chief Operating Officer (COO) and Chief Financial Officer (CFO) of Mariana Oncology and oversaw the company’s acquisition by Novartis in 2024 for $1B upfront and up to $750M in potential milestone payments. She has raised nearly $1B in capital for public and private life science companies over the past 10+ years. Prior to Mariana Oncology, Ms. Bain served as CFO of Codiak BioSciences, CFO of Avalanche Biotechnologies, and Vice President of Finance, Business Operations, and Treasurer at bluebird bio. She previously held senior roles at Genzyme, Fidelity Investments, AstraZeneca and Deloitte & Touche. She is currently on the Board of Directors of Arvinas, Autolus Therapeutics and Hemab Therapeutics.“I am thrilled with the opportunity to contribute my skills and experience to a Company at the forefront of tackling disease drivers with a novel approach, modulating RNA processing with small molecules,” said Ms. Bain. “I look forward to joining the Remix Board of Directors and working with the team to best position the Company to deliver on this important mission and advancing new options for patients in great need of new treatments.” About Remix TherapeuticsRemix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com. Contacts: Media Contact:Lisa BuffingtonBuffington Commslbuffington@remixtx.com Investor Contact:Will O'Connor Precision AQWill.OConnor@precisionaq.com

Backed by Sanofi in its latest funding round, Agomab Therapeutics on Monday reported positive preliminary results from a Phase IIa trial of its lead candidate AGMB-129 for the treatment of fibrostenosing Crohn's disease (FSCD).The STENOVA study is pitting one of two doses of the oral ALK5 inhibitor AGMB-129 against placebo in 90 patients with FSCD for 12 weeks, in addition to standard of care, including biologics. While primary goals include safety and tolerability, secondary endpoints comprise pharmacokinetics and target engagement at ileal strictures assessed via transcriptomics.Agomab noted that interim results from the first 44 participants showed that AGMB-129 met all primary and secondary endpoints versus placebo. “The positive interim data…represent a significant milestone for this programme, and we look forward to presenting the detailed results at a scientific conference in the near-term,” remarked chief medical officer Philippe Wiesel. Meanwhile, the company indicated that it remains on track to report full results from STENOVA in the fourth quarter.According to the company, AGMB-129 is an oral gastrointestinal-restricted ALK5 inhibitor designed to target TGF-β-driven fibrosis with minimal systemic exposure for improved safety. Early-stage clinical testing showed high ileal exposure, good tolerance and no significant systemic presence, highlighting its potential as the first targeted therapy for this condition with an unmet treatment need.Last October, the Belgian biotech raised $89 million in series D funding — with Sanofi pitching in — to advance AGMB-129 in FSCD, along with two other programmes targeting pulmonary and liver fibrosis. Since its founding in 2017, the company has steadily increased its fundraising, from a €21 million ($22.8 million) series A in 2019 to a $74 million series B in 2021, later expanded by $40.5 million. In 2023, it secured $100 million in a series C led by Fidelity.

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a Phase 3 study, and now plans to take the drug to regulators for approval. The study put all patients on the drug, called ecopipam, for a 12-week open-label period. If patients had clinically meaningful reductions in vocal and motor tics during that time, they were then randomized to get either ecopipam or a placebo in a double-blind, 12-week withdrawal period. The trial included 167 pediatric participants and 49 adults in the US, Canada and European Union. In the trial’s primary endpoint, 41.9% of pediatric participants on Emalex’s drug relapsed and 68.1% of pediatric patients on placebo relapsed, Emalex said. A secondary endpoint looked at adult and pediatric patients, and showed similar results: 41.2% of people on the study drug relapsed, whereas 67.9% on placebo relapsed. Emalex said both endpoints were statistically significant. On safety, the company said its drug was “generally well tolerated.” The most common side effects were somnolence (drowsiness or sleepiness), insomnia, anxiety, fatigue and headache. The Chicago-based biotech said it next plans to meet with the FDA and other unnamed global health regulators with the goal of submitting a new drug application for the experimental medicine “later this year.” “We are hopeful that ecopipam can provide symptomatic relief from the tics suffered by patients with Tourette syndrome,” CEO Eric Messner said in a statement. The company didn’t respond to requests for more details about the trial. Tourette syndrome is a neurodevelopmental disorder that can start in childhood and lead to chronic motor and speech tics. Neurocrine and other companies have attempted to make medicines for it, and Noema Pharma is in Phase 2b testing with a different approach. Emalex bought ecopipam from Psyadon in 2018 after the Maryland-based biotech took the investigational treatment through Phase 2b . The drug aims to block dopamine at the D1 receptor. The biotech brought on blue-chip investors in the fall of 2022 to fund the registrational trial after looking at the potential of going public, executives previously told Endpoints News . That year, Bain Capital Life Sciences led a $250 million Series D alongside Emalex’s founder Paragon Biosciences, Valor Equity Partners, Fidelity and “several” family offices. At the time of the Series D, Emalex leaders told Endpoints the funding would take it through the Phase 3 and help support manufacturing and certain pre-commercialization activities. Paragon, a Midwest biotech incubator and investor run by former Marathon Pharmaceuticals leader Jeff Aronin, founded Emalex in 2018 to create new medicines for CNS disorders. Paragon has also backed skin cell therapy company Castle Creek Biosciences , daytime sleepiness drugmaker Harmony Biosciences , AI-driven protein maker Evozyne , and eye and brain disease biotech CiRC Biosciences.